Maxinovel Pharmaceuticals
Latest round
- Series C
Last raised
- Oct 2022
Total raised
- $14M
Investors
- 9
About Maxinovel Pharmaceuticals
Established in 2016 and based in Guangzhou, China, Maxinovel Pharmaceuticals is a medical company that focuses on the research and development of small molecule targeted drugs and tumor immune drugs. The management and technical teams have over 20 years of experience in drug discovery and clinical management. The company has established R&D and operation centers in Shanghai, Guangzhou and Shenzhen. And, we also have offices in the United States and Australia.S. Food and Drug Administration (FDA) for its clinical product Max-40279. The company's co-founder, Chairman and President, Yuguang Wang, graduated from the University of Kansas with over 30 years of experience in new drug development and management, and was the recipient of the 2008 Edison Patent Award for invention. The company's main business is the research and development of acute myeloid leukemia, colorectal cancer, gastric cancer, lung cancer and other fields, products involving tumor targeting, tumor immunity, skin drugs and other innovative drugs. Their self-developed products such as acute myeloid leukemia drug MAX-4, solid tumor targeted therapy drug MAX-5, baldness hair drug MAX-3 and radioligand therapy drug MAX-8. The company generates revenue from producing small molecule innovative drugs: oral drug, transdermal drug and radiopharmaceuticals & radio diagnostics.
Who invested in Maxinovel Pharmaceuticals
9 investors across 4 rounds
See all investors in Maxinovel Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Maxinovel Pharmaceuticals
Who invested in Maxinovel Pharmaceuticals?
Maxinovel Pharmaceuticals has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Maxinovel Pharmaceuticals raised?
Maxinovel Pharmaceuticals has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Maxinovel Pharmaceuticals last raise money?
Maxinovel Pharmaceuticals's most recent round on record is a Series C, in Oct 2022.
What does Maxinovel Pharmaceuticals do?
Established in 2016 and based in Guangzhou, China, Maxinovel Pharmaceuticals is a medical company that focuses on the research and development of small molecule targeted drugs and tumor immune drugs.
Where is Maxinovel Pharmaceuticals headquartered?
Maxinovel Pharmaceuticals is headquartered in Guangzhou, China.
Which VCs invest in companies like Maxinovel Pharmaceuticals?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Maxinovel Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Maxinovel Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.